Panel
Innovating Hope: Charting the New Era of Alzheimer's & Other Dementias | Future of Health Summit
Milken InstituteAllison Aubrey, Kris Engskov, Jessie Fahrbach, Howard Fillit, Richard Isaacson, Joanne Pike, Chris Inskov
- The global population affected by Alzheimer's is projected to double from approximately 7 million to 14 million by 2050, driven by a lack of effective interventions for those past the pre-symptomatic stage, as roughly 72 million boomers will require care over the next few years.
- Disease progression modeling indicates that delaying symptom onset by five years could reduce total Alzheimer's cases by 40%, while combination therapies involving two or three simultaneous drugs are expected to be studied within five years.
- Research focus is shifting upstream toward primary prevention in the 20s, 30s, and 40s, with experts advocating for tracking cholesterol, metabolic, and inflammatory markers during these decades to address brain health issues before pathology develops.
- Clinical trial strategies are undergoing a transformation where 75% of current research targets inflammation and protein misfolding rather than solely beta-amyloid, addressing the reality that 40% of Alzheimer's pathology cases involve faster-progressing Lewy bodies.
- Diagnostic capabilities are evolving through AI predictive analytics, blood biomarkers, and speech pattern databases from 2,000 patients, with a specific industry goal to provide 100 blood tests for approximately $100 to enable scalable, low-cost at-home monitoring.
- Financial commitments include $40 million in additional Alzheimer's Association funding, a US government investment potentially reaching $4 billion (an increase of $100 million over $3.8 billion), and Texas's $3 billion allocation over ten years ($300 million annually).
- The care infrastructure faces a severe supply-demand mismatch where senior care places are expected to be 30 times less than demand, necessitating the development of national infrastructure, specialized clinics, and "dementia built communities" within five years.
- Healthcare delivery models anticipate telehealth as a critical solution for rural and homebound populations, with programs like Guide demonstrating a potential 30% reduction in emergency visits and 15% reduction in hospitalizations.
- Personalized prevention requires multi-marker panels (e.g., p-tau 217, APOE) rather than single tests, acknowledging that women's rapid estrogen withdrawal during perimenopause necessitates precision-based hormone therapy approaches.
- Significant risks include the absence of a defined payer ("care chair") for new care models, the potential harm of over-reliance on black box warnings regarding hormone replacement therapy, and the limitation that current drugs will not benefit patients who have already passed the pre-symptomatic stage.
- Lifestyle interventions such as the engaged group approach in the POINTER study and eating berries twice weekly have shown potential to delay cognitive decline by one to two years, extending into future implementation projects funded by major associations.